膜固思达治疗慢性糜烂性胃炎的疗效观察

Therapeutic effect of mucosta on chronic erosive gastritis

目的:观察新型胃黏膜保护剂膜固思达[成分为瑞巴派特(rebamipide),化学名为2-(4-氯苯甲酰胺基)-3-(1,2-二氯-2-氧代-4-喹啉基)-丙酸]治疗慢性糜烂性胃炎(CEG)8周的疗效。方法:本研究共纳入经内镜确诊的慢性糜烂性胃炎60例。分组给药治疗8周后评估症状改善程度,内镜取胃黏膜标本,观察病理、检测PGE2和MDA水平。结果:56例患者完成8周治疗疗程。试验组与对照组症状均较治疗前有显著性改善(P<0.05),但两组间无明显差异。胃组织病理显示试验组腺体密度和腺体形态恢复明显优于对照组(P<0.05)。试验组与对照组内镜下糜烂愈合总有效率差异无显著性(P>0.05)。试验组和对照组中PGE2及MDA的含量较治疗前均有明显改变(P<0.05),试验组中PGE2的含量较对照组升高明显,MDA的含量较对照组下降明显,试验组与对照组间差异有显著性(P<0.05)。结论:膜固思达对CEG患者的症状有改善作用,促进胃黏膜糜烂的愈合,减轻炎症反应,提高胃黏膜内PGE2水平及降低MDA水平,膜固思达是一种有效的胃黏膜保护剂。

Objective：To investigate the therapeutic effect of Mucosta on chronic erosive gastritis for 8 weeks period. Methods： This study enrolled 60 patients with CEG diagnosed by gastroscopy. After 8 weeks of therapy, the changes of symptoms were observed, and the level of PGE2 and MDA were examined. Results： Fifty-six patients with CEG completed 8 weeks of treatment. In the study group and the control group, symptom scores were significantly decreased （P 〈 0.05）, but there were no significant difference between two groups. A better mucosa restoration on gland density and morphology were observed in the study group （P 〈 0.05 ）at the end of 8 weeks. In both groups, the concentration of PGE2 increased significantly and MDA decreased more than before （P 〈 0.05 ）, and there was significant difference between the study group and the control group in 8 weeks. Conclusion：The gastric protective drug Mucosta can better relieve the symptoms of the patients with CEG, healing the erosive lesion in the stomach, increasing the level of PGE2 and decreasing the level of MDA. Mucosta is an effective drug for CEG.